The cure rates in the clinically evaluable population were similar in the telavancin ( 82.5 % , 231/280 ) and vancomycin ( 81.3 % , 243/299 ) groups [ treatment difference ( 95 % CI ) : 1.3 % ( -5.0 % to 7.6 % ) ] , and were consistent with the overall ATTAIN study results .